Site Under Construction

rTR Technovation Corporation Chosen for Newchip’s Intensive Global Pre-Seed Accelerator Program

Biotechnology company among top applicants selected for Newchip’s online accelerator

Chino, CA, USA, February 28, 2022 - rTR Technovation, a biotech company that develops licensable biomedical technologies to study and mimic mechanisms behind case studies of chronic disease remissions for healthcare, was accepted into Newchip’s renowned global accelerator program. Designed to provide all the skills and tools founders need to rapidly fund, build and scale their companies, past accelerator cohorts averaged more than 17.5 times the average funding amount. The equity-free, fully digital accelerator has helped over 1,500 founders from more than 50 countries and 250 cities raise over $450 million in funding with an estimated portfolio of over $9B.

“Newchip evaluates a diverse number of companies across all industries from around the world, selecting a small percentage to join our accelerator,” says Armando Vera Carvajal, Vice President of Product at Newchip. “This strict selection process makes us an ideal partner for investors looking for promising start-ups. Biotechnology companies like rTR Technovation can scale quickly with proper funding and guidance. We are excited for rTR Technovation and believe they will do well at Newchip.”

“Being accepted into the Newchip Accelerator, we are excited to strengthen our business network, and learn from our peers and mentors," says Paul C Lee, founder and CEO, "This is an essential process to secure funding in order to maximize our chance for success and help others."

About rTR Technovation

rTR Technovation is a biotechnology pre-seed startup that researches case studies of chronic disease remission (various cancers, diabetes, CAD, etc) in order to develop technology for better and earlier detection and therapeutic strategies. Its first product is an intravenous custom-shaped nanoparticle platform for use as a molecular imaging research tool, which in the future, can be used as a therapeutic carrier. The platform's shape and features addresses limitations found in conventional vascular-targeting nanoparticles, for binding to blood vessels at the early stages of inflammation. rTR Technovation has submitted an NSF SBIR Phase I grant to optimize their minimally viable product, and are awaiting review and approval. Development of this technology will in theory be an important starting point to address the growing crisis of both long-COVID and various chronic diseases.

About Newchip

Newchip is an online, global startup accelerator led by a world-class team of entrepreneurs and investors. It was designed to provide founders with the tools needed to rapidly fund, build, and scale. Since its inception in 2019, the equity-free, remote accelerator has enabled over 1,500 startups from 50+ countries to raise over $450 million in funding with an estimated $9B portfolio. It has three distinct six-month accelerator programs based on company stage: Pre-Seed, Seed, and Series A. Its vast network of global investors, strategic partners, and mentors guide companies from team building and prototype development to securing high-profile VC investment, corporate partnerships, and everything in-between. To learn more, visit https://launch.newchip.com/.